2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH DENA BATTLE
Patient Perspectives on Cytoreductive Nephrectomy after the CARMENA Trial

VIEW ALL ASCO GU 2019 VIDEOS

Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH OLIVER SARTOR
Overall Survival Benefit and Racial Disparities in African American Men with Metastatic Prostate Cancer

VIEW ALL PCF VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH KARIM FIZAZI
ARAMIS - Efficacy and Safety of Darolutamide in nmCRPC

VIEW ALL ASCO GU 2019 VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH JAMES GULLEY
Immunotherapy Across Genitourinary Malignancies

VIEW ALL ASCO GU 2019 VIDEOS

Featured Videos

#AUA14 - The role of obesity in the incidence of lymphatic spread, disease-free and overall survival: Data from the ARISER clinical trial - Session Highlights

ORLANDO, FL USA (UroToday.com) - The relationship between obesity and high-risk clear cell type RCC is not clear. Karim Chamie and colleagues studied the association of obesity with lymphatic spread and survival in patients from an international phase III clinical trial which tested the efficacy of cG250 antibodies in patients with high risk for recurrence of high-risk clear cell RCC.

auaThe authors reviewed clinical and pathologic records of 864 patients from the phase III clinical trial. They assessed patient BMI in addition to other demographic status. BMI was stratified into widely accepted BMI groups. They then calculated for the association between BMI, severity of disease, and survival in patients with clear cell RCC.

They found that majority of patients were overweight and obese. Interestingly, they found that increasing BMI led to a decrease incidence of lymphatic spread in their cohort of patients. Furthermore, obesity was associated with improved disease-free and overall survival.

The authors concluded that in their cohort of patients, for those who had had nephrectomies for RCC, obesity was beneficial. This is a very interesting finding as previous belief has been that obesity is associated with higher risk of having kidney cancer. The results of the study may indicate that BMI is not a good indicator of kidney cancer. Taking into account the weight loss of patients is necessary to confirm the conclusions from the study, patients in the obese category may not have lost as much weight, a factor that is usually associated with worsening disease.

Presented by Karim Chamie, MD at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

Los Angeles, CA USA

Written by Garen Abedi, MD, University of California (Irvine), and medical writer for UroToday.com

 

Conference Coverage
 
Recent data from conferences worldwide
Journals
Publications focusing on urologic cancer treatments through original manuscripts
Everyday Urology Volume 3 Issue 4

Everyday Urology™ - Oncology Insights

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe